UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 94,874,045	$ 108,230,714
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	25,509,069	23,953,768
(Gain) on disposal of assets	(24,367)	(25,671)
Loss on disposal of assets	0	6,838
(Gain) on sale of investments and technology investment income	(787,579)	(4,687,471)
Loss on sale of investments and technology investment losses	3,274,941	10,384,965
Deferred tax expense	(927,401)	(3,638,218)
Stock-based compensation expense related to employee stock options, employee stock purchases and restricted stock	8,671,763	10,473,792
Change in operating assets and liabilities:
Accounts receivable, net	(35,280,995)	(19,781,263)
Inventories	27,562,638	(34,064,216)
Prepaid expenses and other	9,056,108	4,663,897
Accounts payable	(3,809,528)	6,080,702
Accrued liabilities, excluding dividends declared	20,386,827	28,279,293
Net cash provided by operating activities	148,505,521	129,877,130
Activity in investments:
Sales proceeds	48,810,102	16,121,684
Maturities and calls	0	1,420,000
Purchases	(12,180,407)	(37,537,250)
Plant and equipment additions	(36,722,401)	(31,871,370)
Proceeds from sale of plant and equipment	53,110	9,500
Increase in other assets	(5,061,949)	(3,285,058)
Net cash used for investing activities	(5,101,545)	(55,142,494)
CASH FLOWS USED FOR FINANCING ACTIVITIES:
Issuance of common stock from stock plan transactions	4,933,702	16,833,987
Cash dividends paid	(27,264,150)	(27,774,268)
Repurchases of common stock	(67,833,696)	(41,224,840)
Net cash used for financing activities	(90,164,144)	(52,165,121)
NET INCREASE IN CASH AND CASH EQUIVALENTS	53,239,832	22,569,515
CASH, CASH EQUIVALENTS, and RESTRICTED CASH, beginning of period	233,318,766	226,435,019
CASH, CASH EQUIVALENTS, and RESTRICTED CASH, end of period	286,558,598	249,004,534
Non-cash investing and financing activities:
Change in property and equipment in accounts payable and accrued expenses and other current liabilities	$ 9,778,725	$ 557,154

GENTEX CORP 10-Q